

# Manel SabatÃ© Tenas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3504496/publications.pdf>

Version: 2024-02-01

423  
papers

27,733  
citations

15504  
65  
h-index

6131  
159  
g-index

454  
all docs

454  
docs citations

454  
times ranked

18222  
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with <i>de novo</i> three-vessel disease: final results of the SYNTAX II study. European Heart Journal, 2022, 43, 1307-1316.	2.2	54
2	Outcomes of Nonagenarians With Acute Coronary Syndrome. Journal of the American Medical Directors Association, 2022, 23, 81-86.e4.	2.5	6
3	Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 (English Ed ), 2022, 75, 515-522.	0.6	11
4	Combined left atrial appendage occlusion with other transseptal procedures: should we use the same transseptal puncture?. Revista Espanola De Cardiologia (English Ed ), 2022, 75, 181-182.	0.6	0
5	The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. Cardiovascular Revascularization Medicine, 2022, 39, 106-113.	0.8	5
6	Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. European Heart Journal, 2022, 43, 1320-1330.	2.2	26
7	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	2.7	1
8	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
9	Spontaneous Coronary Artery Dissection: Rediscovering an old cause of myocardial infarction. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	1.3	2
10	Coronary Microvascular Angina: A State-of-the-Art Review. Frontiers in Cardiovascular Medicine, 2022, 9, 800918.	2.4	6
11	A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emergency Medicine Journal, 2022, 39, 402-410.	1.0	5
12	Sirolimus Versus Paclitaxel. JACC: Cardiovascular Interventions, 2022, 15, 780-782.	2.9	2
13	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed ), 2022, , .	0.6	5
14	Overlapping versus single long stents in long chronic total occlusions: insights of the Iberian CTO Registry. Minerva Cardiology and Angiology, 2022, , .	0.7	0
15	Transcatheter mitral valve repair in nonagenarians.. Journal of Geriatric Cardiology, 2022, 19, 90-94.	0.2	0
16	Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial. EuroIntervention, 2022, 18, e389-e396.	3.2	9
17	Atrial fibrillation and acute coronary syndromes in nonagenarians. European Heart Journal: Acute Cardiovascular Care, 2022, 11, .	1.0	0
18	Amphilimus- versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. Cardiovascular Revascularization Medicine, 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
19	Circulating miRNA Fingerprint and Endothelial Function in Myocardial Infarction: Comparison at Acute Event and One-Year Follow-Up. <i>Cells</i> , 2022, 11, 1823.	4.1	4
20	Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 766-773.	1.7	4
21	Survival benefit of revascularization versus optimal medical therapy alone for chronic total occlusion management in patients with diabetes. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 376-383.	1.7	6
22	Two-year outcomes after percutaneous coronary intervention with drug-eluting stents or bare-metal stents in elderly patients with coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E607-E613.	1.7	0
23	Prognosis of Patients With Reduced Left Ventricular Ejection Fraction and Chronic Total Occlusion According to Treatment Applied. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 22-27.	0.8	3
24	Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension. <i>Translational Research</i> , 2021, 228, 64-75.	5.0	2
25	Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter?. <i>International Journal of Cardiology</i> , 2021, 325, 9-15.	1.7	4
26	Longitudinal Neointimal Distribution Pattern After Everolimus-Eluting Stent Implantation: Insights From Optical Coherence Tomography Study. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 17-23.	0.8	2
27	Sex-gender disparities in nonagenarians with acute coronary syndrome. <i>Clinical Cardiology</i> , 2021, 44, 371-378.	1.8	11
28	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	1.7	6
29	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 1013-1022.	0.6	4
30	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	2.8	32
31	Funci3n endotelial y microvascular distal a stents farmacoactivos sin pol3mero y captadores de c3lulas endoteliales. Estudio aleatorizado FUNCOMBO. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 1014-1023.	1.2	2
32	Impact of diabetes mellitus on vascular healing process after everolimus-eluting stent implantation: An optical coherence tomography study. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.8	1
33	Acute coronary syndrome in nonagenarians: gender gap?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, .	1.0	0
34	Outcomes in nonagenarians with acute coronary syndrome. Is medical treatment important?. <i>European Journal of Preventive Cardiology</i> , 2021, 28, .	1.8	0
35	International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2466-2476.	2.8	78
36	Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2096.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 2276.	2.4	9
38	Anatomical Fusion of MitraClip Device With Native Mitral Apparatus. JACC: Cardiovascular Interventions, 2021, 14, 1257-1258.	2.9	0
39	Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. EuroIntervention, 2021, 17, 233-239.	3.2	4
40	Impact of chronic kidney disease in chronic total occlusion management and clinical outcomes. Cardiovascular Revascularization Medicine, 2021, , .	0.8	3
41	Long-term vascular function in CTO recanalization: A randomized clinical trial of ticagrelor vs. clopidogrel. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
42	Plaque modification in calcified chronic total occlusions: the PLACCTON study. Revista Espanola De Cardiologia (English Ed ), 2021, 75, 213-213.	0.6	1
43	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. PLoS ONE, 2021, 16, e0255263.	2.5	12
44	New Interventional Therapies beyond Stenting to Treat ST-Segment Elevation Acute Myocardial Infarction. Journal of Cardiovascular Development and Disease, 2021, 8, 100.	1.6	5
45	Drug-Coated Balloon for Diabetic Patients With Small Coronary Vessels. JACC: Cardiovascular Interventions, 2021, 14, 1799-1800.	2.9	2
46	Los implantes valvulares transcatheter en el 2021: una realidad cuyos límites aún desconocemos. Medicina Clínica, 2021, 157, 535-536.	0.6	0
47	Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program. Journal of Clinical Medicine, 2021, 10, 4252.	2.4	7
48	Amplatzer Vascular Plug III and Interclip Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, e9-e10.	2.9	2
49	Acute and Chronic Effects of COVID-19 on the Cardiovascular System. Journal of Cardiovascular Development and Disease, 2021, 8, 128.	1.6	16
50	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e018828.	3.7	4
51	Low Dose of Direct Oral Anticoagulants after Left Atrial Appendage Occlusion. Journal of Cardiovascular Development and Disease, 2021, 8, 142.	1.6	11
52	Spanish Cardiac Catheterization and Coronary Intervention Registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 1095-1105.	0.6	2
53	Treatment of device related thrombosis after left atrial appendage occlusion: Initial experience with low-dose apixaban. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
54	Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. Journal of the American Heart Association, 2021, 10, e022123.	3.7	4

#	ARTICLE	IF	CITATIONS
55	Linking In Vitro Models of Endothelial Dysfunction with Cell Senescence. <i>Life</i> , 2021, 11, 1323.	2.4	5
56	Clinical Impact of Medical Therapy Versus Revascularization in Patients With Chronic Coronary Total Occlusions. <i>Journal of Invasive Cardiology</i> , 2021, 33, E2-E8.	0.4	1
57	Recurrent atherosclerosis complications as a mechanism for stent failure. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 9-14.	1.0	12
58	Safety and outcomes of MitraClip implantation in functional mitral regurgitation according to degree of left ventricular dysfunction. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 530-535.	0.6	5
59	Outcomes of Nonagenarians With ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 125, 11-18.	1.6	17
60	Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia. <i>Basic Research in Cardiology</i> , 2020, 115, 2.	5.9	26
61	Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent. <i>Atherosclerosis</i> , 2020, 312, 79-89.	0.8	3
62	Delayed Mitral Leaflet Perforation in a Tethered Valve After MitraClip XTR Implantation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2438-2439.	2.9	3
63	MitraClip Implantation for Hemolytic Anemia Treatment After Surgical Mitral Valve Repair. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, e85-e86.	2.9	1
64	Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial. <i>American Heart Journal</i> , 2020, 227, 111-117.	2.7	10
65	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1609-1621.	2.8	75
66	Response by Ortega-Paz et al to Letter Regarding Article, "Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial". <i>Circulation</i> , 2020, 141, e748-e749.	1.6	0
67	Very-late restenosis of a magnesium-based resorbable scaffold. <i>European Heart Journal</i> , 2020, 41, 2602-2602.	2.2	1
68	Sex-based differences in chronic total occlusion management and long-term clinical outcomes. <i>International Journal of Cardiology</i> , 2020, 319, 46-51.	1.7	11
69	Kv1.3 blockade inhibits proliferation of vascular smooth muscle cells in vitro and intimal hyperplasia in vivo. <i>Translational Research</i> , 2020, 224, 40-54.	5.0	11
70	Unravelling the best management strategy for older patients with acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 478-479.	1.0	0
71	Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1386-1402.	2.8	30
72	Late Cerebrovascular Events Following Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 872-881.	2.9	25

#	ARTICLE	IF	CITATIONS
73	Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1792.	2.4	4
74	Moderate Hypothermia Modifies Coronary Hemodynamics and Endothelium-Dependent Vasodilation in a Porcine Model of Temperature Management. <i>Journal of the American Heart Association</i> , 2020, 9, e014035.	3.7	6
75	Comparison of Transfemoral Versus Transradial Secondary Access in Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008609.	3.9	21
76	Very Late Outcomes After Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 605-607.	2.8	1
77	Comparison of clinical outcomes in STEMI patients treated with primary PCI according to day-time of medical attention and its relationship with circadian pattern. <i>International Journal of Cardiology</i> , 2020, 305, 35-41.	1.7	3
78	Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. <i>American Heart Journal</i> , 2020, 222, 174-182.	2.7	7
79	Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008620.	3.9	43
80	Inpatient Randomization to Study Strut Coverage in Polymer-Free Versus Biodegradable-Polymer Sirolimus-Eluting Stent Implantations. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 899-900.	2.9	3
81	Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. <i>Scientific Reports</i> , 2020, 10, 5373.	3.3	58
82	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. <i>EuroIntervention</i> , 2020, 15, 1451-1457.	3.2	14
83	Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. <i>EuroIntervention</i> , 2020, 16, e155-e163.	3.2	7
84	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 15, e1605-e1614.	3.2	20
85	Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. <i>EuroIntervention</i> , 2020, 15, 1436-1443.	3.2	13
86	Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. <i>EuroIntervention</i> , 2020, 16, e913-e921.	3.2	16
87	A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial. <i>EuroIntervention</i> , 2020, 16, e997-e1004.	3.2	6
88	The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention. <i>European Heart Journal Supplements</i> , 2020, 22, P13-P18.	0.1	4
89	Thrombotic and Bleeding Events After Percutaneous Coronary Intervention in Out-of-hospital Cardiac Arrest With and Without Therapeutic Hypothermia. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 433-435.	0.6	1
90	Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 373-382.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Minimally-invasive Transesophageal Echocardiography for Left Atrial Appendage Occlusion With a Latest-generation Microprobe. Initial Experience. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 511-512.	0.6	5
92	Intravenous Statin Administration During Ischemia Exerts Cardioprotective Effects. Journal of the American College of Cardiology, 2019, 74, 475-477.	2.8	12
93	Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial. Value in Health, 2019, 22, 1355-1361.	0.3	3
94	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2019, 12, e007705.	3.9	6
95	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
96	Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction. Circulation, 2019, 140, 1904-1916.	1.6	74
97	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
98	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
99	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine, 2019, 381, 1820-1830.	27.0	523
100	Impact of postprocedural minimal stent area on 2-year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
101	Unravelling the pathophysiology of spontaneous coronary artery dissections. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 604-605.	0.6	0
102	Eventos trombóticos y hemorrágicos después de una intervención coronaria percutánea tras parada cardíaca extrahospitalaria con y sin hipotermia terapéutica. Revista Espanola De Cardiologia, 2019, 72, 433-435.	1.2	2
103	Minimally Invasive Transradial Percutaneous Closure of an Aortic Paravalvular Leak After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2019, 35, 941.e1-941.e2.	1.7	6
104	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet, The, 2019, 393, 2503-2510.	13.7	166
105	Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. Catheterization and Cardiovascular Interventions, 2019, 94, 917-925.	1.7	5
106	Impact of revascularization versus medical therapy alone for chronic total occlusion management in older patients. Catheterization and Cardiovascular Interventions, 2019, 94, 527-535.	1.7	15
107	Multivessel spontaneous coronary artery dissection involving the left main coronary artery: a case report. European Heart Journal - Case Reports, 2019, 3, yty168.	0.6	4
108	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. Journal of the American College of Cardiology, 2019, 73, 1616-1628.	2.8	60



#	ARTICLE	IF	CITATIONS
109	How to SORT OUT an Additional Value From Noninferiority Stent Comparisons?. JACC: Cardiovascular Interventions, 2019, 12, 634-636.	2.9	0
110	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
111	MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. Catheterization and Cardiovascular Interventions, 2019, 93, 64-70.	1.7	10
112	Comparison of the Frequency of Thrombocytopenia After Transfemoral Transcatheter Aortic Valve Implantation Between Balloon-Expandable and Self-Expanding Valves. American Journal of Cardiology, 2019, 123, 1120-1126.	1.6	17
113	Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. Basic Research in Cardiology, 2019, 114, 5.	5.9	16
114	Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon-expandable and self-expanding valves. Catheterization and Cardiovascular Interventions, 2019, 93, 1344-1351.	1.7	11
115	Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 317-323.	0.6	7
116	Spontaneous coronary artery dissection: Not so infrequent to be ignored. Medicina Clínica, 2019, 153, 245-249.	0.6	7
117	Ecocardiografía transesofágica mínimamente invasiva con microsonda de última generación para el cierre percutáneo de la orejuela izquierda. Experiencia inicial. Revista Espanola De Cardiologia, 2019, 72, 511-512.	1.2	6
118	Descifrando la fisiopatología de la disección coronaria espontánea. Revista Espanola De Cardiologia, 2019, 72, 604-605.	1.2	2
119	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e539-e546.	3.2	16
120	New percutaneous interventions in heart failure. Minerva Cardioangiologica, 2019, 67, 145-162.	1.2	1
121	Clinical, Angiographic, and Procedural Correlates of Very Late Absorbable Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2018, 11, 638-644.	2.9	20
122	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
123	In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 917-925.	0.6	3
124	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq0 0 0 rBT /Overlock 10 Tf Cardiology, 2018, 121, 1039-1045.	1.6	10
125	Falsos positivos en la activación por IAMCEST en una red regional: análisis integral e impacto clínico. Resultados del registro Codi Infart de Cataluña. Revista Espanola De Cardiologia, 2018, 71, 243-249.	1.2	10
126	Análisis morfológico y funcional de la arteria descendente anterior de pacientes con síndrome de tako-tsubo. Revista Espanola De Cardiologia, 2018, 71, 986-988.	1.2	3



#	ARTICLE	IF	CITATIONS
127	Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 327-334.	0.6	1
128	False Positive STEMI Activations in a Regional Network: Comprehensive Analysis and Clinical Impact. Results From the Catalanian Codi Infart Network. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 243-249.	0.6	9
129	TlcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGERâ€œBVS trial): Rationale and study design. Catheterization and Cardiovascular Interventions, 2018, 91, 1-6.	1.7	6
130	Threeâ€œand 6â€œmonth optical coherence tomographic surveillance following percutaneous coronary intervention with the AngioliteÂ® drugâ€œeluting stent: The ANCHOR study. Catheterization and Cardiovascular Interventions, 2018, 91, 435-443.	1.7	7
131	Angina e isquemia a los 2 aÃ±os con armazÃ³n vascular bioabsorbible y stents farmacoactivos metÃ¡licos. Estudio ESTROFA Isquemia AVB-SFam. Revista Espanola De Cardiologia, 2018, 71, 327-334.	1.2	3
132	Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet, The, 2018, 391, 41-50.	13.7	307
133	Tricuspid Percutaneous Repair With the MitraClip System: First Implant in Spain. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 976-977.	0.6	1
134	Functional and Morphological Assessment of Left Anterior Descending Artery in Patients With Tako-tsubo Syndrome. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 986-988.	0.6	2
135	CorrecciÃ³n de fugas paravalvulares: buscando el equilibrio entre las tÃ©cnicas quirÃºrgicas y percutÃ¡neas. Revista Espanola De Cardiologia, 2018, 71, 679-681.	1.2	1
136	Pulmonary function predicts mortality and hospitalizations in outpatients with heart failure and preserved ejection fraction. Respiratory Medicine, 2018, 134, 124-129.	2.9	9
137	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <sc>E</sc>uropean <sc>M</sc>ulticentre <sc>GHOST</sc>â€œ<sc>EU</sc> <sc>R</sc>egistry. Catheterization and Cardiovascular Interventions, 2018, 91, 444-453.	1.7	8
138	ReparaciÃ³n percutÃ¡nea de la vÃ¡lvula tricÃ©spide con el sistema MitraClip: primer implante en EspaÃ±a. Revista Espanola De Cardiologia, 2018, 71, 976-977.	1.2	3
139	EvaluaciÃ³n del efecto sinÃ©rgico de la metformina y los inhibidores mTOR sobre la endotelizaciÃ³n de los stents farmacoactivos en pacientes diabÃ©ticos. Revista Espanola De Cardiologia, 2018, 71, 917-925.	1.2	2
140	Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open, 2018, 8, e020255.	1.9	22
141	Thrombectomy and Stroke. Journal of the American College of Cardiology, 2018, 72, 1597-1599.	2.8	4
142	Percutaneous coronary intervention due to chronic total occlusion in the left main coronary artery after bypass grafting: A feasible option in selected cases. Revista Portuguesa De Cardiologia, 2018, 37, 865.e1-865.e4.	0.5	2
143	Latest STEMI treatment: a focus on current and upcoming devices. Expert Review of Medical Devices, 2018, 15, 807-817.	2.8	11
144	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function andÂœOther Vascular Biomarkers. JACC: Cardiovascular Interventions, 2018, 11, 1576-1586.	2.9	43

#	ARTICLE	IF	CITATIONS
145	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. JACC: Cardiovascular Interventions, 2018, 11, 1559-1571.	2.9	29
146	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With Durable Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2018, 11, 995-1002.	2.9	63
147	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. Journal of the American College of Cardiology, 2018, 71, 2756-2769.	2.8	92
148	The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. JACC: Cardiovascular Interventions, 2018, 11, 1013-1015.	2.9	2
149	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease. JACC: Cardiovascular Interventions, 2018, 11, 1234-1243.	2.9	58
150	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. American Heart Journal, 2018, 204, 205-209.	2.7	4
151	Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. Journal of Clinical Medicine, 2018, 7, 27.	2.4	10
152	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS ONE, 2018, 13, e0201985.	2.5	3
153	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal, 2018, 39, 3381-3389.	2.2	29
154	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
155	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
156	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the GHOST-EU registry. Catheterization and Cardiovascular Interventions, 2018, 92, 276-282.	1.7	4
157	Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up. EuroIntervention, 2018, 14, 206-214.	3.2	3
158	Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. EuroIntervention, 2018, 14, e570-e579.	3.2	24
159	First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. EuroIntervention, 2018, 13, 2026-2035.	3.2	17
160	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	3.2	7
161	Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention, 2018, 13, 1561-1564.	3.2	45
162	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial. EuroIntervention, 2018, 14, 678-685.	3.2	12

#	ARTICLE	IF	CITATIONS
163	Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial). <i>EuroIntervention</i> , 2018, 14, e1224-e1226.	3.2	14
164	The future of vascular restoration therapy. <i>EuroIntervention</i> , 2018, 14, e976-e979.	3.2	2
165	Paravalvular Leak Correction: Searching for a Balance Between Surgical and Percutaneous Techniques. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 679-681.	0.6	2
166	MitraClip® Repair in Cardiogenic Shock Due to Acute Mitral Regurgitation: From Near-Death to Walking. <i>Journal of Heart Valve Disease</i> , 2018, 27, 114-116.	0.5	4
167	«No Country for Old Men» With ST-segment Elevation Myocardial Infarction. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 70-71.	0.6	0
168	«No es pañs para viejos» con infarto agudo de miocardio y elevaci3n del segmentoÂST. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 70-71.	1.2	7
169	Endothelial function impairment in STEMI patients with out-of-hospital cardiac arrest under therapeutic hypothermia treatment. <i>International Journal of Cardiology</i> , 2017, 232, 70-75.	1.7	5
170	Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	18
171	A longer look at trial evidence of bioresorbable vascular scaffolds. <i>Heart</i> , 2017, 103, 1061-1062.	2.9	2
172	Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. <i>Resuscitation</i> , 2017, 114, 141-145.	3.0	30
173	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	2.9	16
174	Intracoronary Administration of Allogeneic Adipose Tissueâ€Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	43
175	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	2.8	132
176	IMPACT OF FINAL MINIMAL STENT AREA BY IVUS ON 3-YEAR OUTCOME AFTER PCI OF LEFT MAIN CORONARY ARTERY DISEASE: THE EXCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 963.	2.8	22
177	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. <i>European Heart Journal</i> , 2017, 38, 3124-3134.	2.2	244
178	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1809-1815.	2.9	26
179	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1867-1877.	2.9	13
180	Bioresorbable Vascular Scaffold Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1865-1866.	2.9	1

#	ARTICLE	IF	CITATIONS
181	Percutaneous Treatment of Extremely Small Coronary Vessels. JACC: Cardiovascular Interventions, 2017, 10, 1389-1391.	2.9	3
182	Acute coronary syndrome in dextrocardia and situs inversus patient. Medicina Clínica (English) Tj ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 70	0.2	0
183	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	1.6	20
184	Comments on the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation. Revista Espanola De Cardiologia (English Ed ), 2017, 70, 1039-1045.	0.6	6
185	Three-dimensional printing of an aortic model for transcatheter aortic valve implantation: possible clinical applications. International Journal of Cardiovascular Imaging, 2017, 33, 283-285.	1.5	18
186	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 812-818.	1.7	15
187	Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 994-1002.	1.7	9
188	ST-segment elevation mimicking myocardial infarction after hydrochloric acid ingestion: Acute caustic myocarditis. Journal of Cardiovascular Computed Tomography, 2017, 11, 70-71.	1.3	1
189	Síndrome coronario agudo en paciente con dextrocardia y situs inversus. Medicina Clínica, 2017, 148, e69.	0.6	0
190	Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study. Cardiovascular Revascularization Medicine, 2017, 18, 47-52.	0.8	1
191	Comentarios a la guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Revista Espanola De Cardiologia, 2017, 70, 1039-1045.	1.2	12
192	Bioresorbable scaffolds: should we stay simple or go complex?. Cardiovascular Diagnosis and Therapy, 2017, 7, E7-E12.	1.7	0
193	Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: pooled analysis of COMFORTABLE AMI and EXAMINATION. EuroIntervention, 2017, 12, 1577-1586.	3.2	3
194	A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EuroIntervention, 2017, 12, 1587-1594.	3.2	11
195	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention, 2017, 13, e557-e563.	3.2	8
196	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. EuroIntervention, 2017, 13, e1104-e1111.	3.2	9
197	Spain: coronary and structural heart interventions from 2010 to 2015. EuroIntervention, 2017, 13, Z64-Z69.	3.2	7
198	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention, 2017, 12, 2110-2117.	3.2	114

#	ARTICLE	IF	CITATIONS
199	The SYNERGY II Everolimus eluting stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study. EuroIntervention, 2017, 12, 1614-1622.	3.2	9
200	Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. Moving to the percutaneous approach. EuroIntervention, 2017, 13, 1365-1366.	3.2	0
201	Initial Results of Combined MitraClip® Implantation and Left Atrial Appendage Occlusion. Journal of Heart Valve Disease, 2017, 26, 169-174.	0.5	2
202	Bioresorbable vascular scaffolds technology: current use and future developments. Medical Devices: Evidence and Research, 2016, Volume 9, 185-198.	0.8	8
203	Puncture Versus Surgical Cutdown Complications of Transfemoral Aortic Valve Implantation (from) Tj ETQq1 1 0.784314 rgBJ19/Overlock	1.6	19
204	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. Journal of the American College of Cardiology, 2016, 68, B169-B170.	2.8	2
205	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	1.7	20
206	Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?. Cardiovascular Revascularization Medicine, 2016, 17, 571-573.	0.8	1
207	Five-Year Optical Coherence Tomography in Patients With ST-Segment Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	22
208	Sex differences in angiotensin II responses contribute to a differential regulation of cox-mediated vascular dysfunction during aging. Experimental Gerontology, 2016, 85, 71-80.	2.8	13
209	Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?. International Journal of Cardiology, 2016, 223, 226-227.	1.7	4
210	Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome. Resuscitation, 2016, 106, 108-112.	3.0	13
211	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, The, 2016, 388, 2479-2491.	13.7	451
212	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	27.0	843
213	The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 108-116.	4.0	3
214	Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic Research in Cardiology, 2016, 111, 49.	5.9	36
215	Outcomes in the EXAMINATION trial – Authors' reply. Lancet, The, 2016, 387, 1998.	13.7	0
216	Overtime evaluation of the vascular HEALing process after everolimus-eluting stent implantation by optical coherence tomography. The HEAL-EES study. Cardiovascular Revascularization Medicine, 2016, 17, 241-247.	0.8	9



#	ARTICLE	IF	CITATIONS
217	Minimally Invasive Transradial Percutaneous Closure of Aortic Paravalvular Leaks: Following the Steps of Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2016, 32, 1575.e17-1575.e19.	1.7	4
218	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction TROFI II trial. European Heart Journal, 2016, 37, 229-240.	2.2	197
219	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	2.9	68
220	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	2.9	23
221	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet, The, 2016, 387, 357-366.	13.7	174
222	Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction. International Journal of Cardiology, 2016, 202, 517-518.	1.7	13
223	Benefits of chronic total coronary occlusion percutaneous intervention in patients with heart failure and reduced ejection fraction: insights from a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 78.	3.3	30
224	The 2011-2012 pilot European Society of Cardiology Sentinel Registry of Transcatheter Aortic Valve Implantation: 12-month clinical outcomes. EuroIntervention, 2016, 12, 79-87.	3.2	18
225	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. EuroIntervention, 2016, 12, 482-489.	3.2	25
226	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention, 2016, 12, e550-e556.	3.2	32
227	Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention, 2016, 12, 1102-1107.	3.2	46
228	Virtual Histology (VH) for Detecting Necrotic Core (NC). , 2016, , 877-896.		0
229	Bioresorbable vascular scaffolds in clinical practice: state-of-the-art. Panminerva Medica, 2016, 58, 130-42.	0.8	2
230	ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2015, 79, 263-270.	1.6	16
231	Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the CatalanCodi Infartnetwork. BMJ Open, 2015, 5, e009148.	1.9	17
232	Bioresorbable drug-eluting stent implantation technique: In search of a magic recipe. Cardiovascular Revascularization Medicine, 2015, 16, 439-440.	0.8	1
233	Impact of the "ACT NOW. SAVE A LIFE" public awareness campaign on the performance of a European STEMI network. International Journal of Cardiology, 2015, 197, 110-112.	1.7	11
234	Prognosis of new-onset heart failure outpatients and collagen biomarkers. European Journal of Clinical Investigation, 2015, 45, 842-849.	3.4	19

#	ARTICLE	IF	CITATIONS
235	Rationale and study design of the <scp>RESERVOIR</scp> trial: A randomized trial comparing reservoirâ€based polymerâ€free amphiphilicâ€eluting stents versus everolimusâ€eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2015, 85, E116-22.	1.7	8
236	Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. Postepy W Kardiologii Interwencyjnej, 2015, 3, 161-169.	0.2	9
237	Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart, 2015, 101, 1395-1405.	2.9	115
238	Changes in thrombus composition and profilin-1 release in acute myocardial infarction. European Heart Journal, 2015, 36, 965-975.	2.2	52
239	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent inÂST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	2.9	145
240	Association of Myocardial T1-Mapping CMR With Hemodynamics and RV Performance in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 76-82.	5.3	71
241	Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. International Journal of Cardiovascular Imaging, 2015, 31, 239-246.	1.5	8
242	CT coronary angiography increases diagnostic certainty in patients with stable chest pain. Evidence-Based Medicine, 2015, 20, 187-187.	0.6	1
243	Platelet reactivity assessment with VerifyNowÂ®: Substitute or complement for light transmission aggregometry?. International Journal of Cardiology, 2015, 178, 221-222.	1.7	0
244	Percutaneous Mitral Valve Repair for Acute Mitral Regurgitation After an Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 66, 91-92.	2.8	45
245	Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 193-199.	0.2	1
246	Ventricular Restoration: New Therapeutic Approaches. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 257-259.	0.6	1
247	Influencia del sexo en los resultados clÃnicos de los stents liberadores de everolimus en comparaciÃn con los stents metÃlicos sin recubrimiento en el infarto agudo de miocardio con elevaciÃn del segmento ST. Perspectivas del ensayo EXAMINATION. Revista Espanola De Cardiologia, 2015, 68, 382-389.	1.2	11
248	RestauraciÃn ventricular: nuevos enfoques terapÃuticos. Revista Espanola De Cardiologia, 2015, 68, 257-259.	1.2	0
249	Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314 8gBT /Overl	0.784314	8gBT /Overl
250	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2015, 8, e001441.	3.9	172
251	Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity. Journal of Infection, 2015, 70, 565-576.	3.3	30
252	Very Late Scaffold Thrombosis. Journal of the American College of Cardiology, 2015, 66, 1901-1914.	2.8	186



#	ARTICLE	IF	CITATIONS
253	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	27.0	334
254	Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, 1053-1063.	2.9	36
255	Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial. Revista Portuguesa De Cardiologia, 2015, 34, 193-199.	0.5	1
256	Everolimus-eluting stent versus bare-metal stent in elderly ( $\geq 75$ years) versus non-elderly ( $< 75$ years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology, 2015, 179, 73-78.	1.7	17
257	Radial Versus Femoral Access for Angioplasty of ST-segment Elevation Acute Myocardial Infarction With Second-generation Drug-eluting Stents. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 47-53.	0.6	5
258	How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?. EuroIntervention, 2015, 10, e1-e6.	3.2	2
259	Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. EuroIntervention, 2015, 11, 391-398.	3.2	12
260	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
261	Virtual Histology (VH) for Detecting Necrotic Core (NC). , 2015, , 1-20.		0
262	Double atrial septum or redundant Eustachian valve: procedural management during atrial septal defect occlusion. EuroIntervention, 2015, 11, e1-e2.	3.2	0
263	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ, The, 2014, 349, g6427-g6427.	6.0	82
264	Selected CD133 <sup>+</sup> Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina. Circulation Research, 2014, 115, 950-960.	4.5	63
265	Recanalized Thrombus Treated With Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 1453-1455.	2.9	10
266	Randomized Comparison of radial vs. femoral Access for Routine Catheterization of Heart Transplant Patients (RADIAL vs Heart Transplant Study). Transplantation Proceedings, 2014, 46, 3262-3267.	0.6	5
267	Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. Circulation: Cardiovascular Interventions, 2014, 7, 312-321.	3.9	15
268	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275
269	Eficacia y seguridad a más de 10 años de la ablación septal percutánea en la miocardiopatía hipertrófica obstructiva. Revista Espanola De Cardiologia, 2014, 67, 353-358.	1.2	13
270	Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. International Journal of Cardiovascular Imaging, 2014, 30, 469-476.	1.5	23

#	ARTICLE	IF	CITATIONS
271	Distal side-branch technique: A new use for the Tornus® Catheter. Cardiovascular Revascularization Medicine, 2014, 15, 97-99.	0.8	1
272	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 55-63.	2.9	96
273	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. Journal of the American College of Cardiology, 2014, 63, 299-307.	2.8	269
274	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. International Journal of Cardiology, 2014, 177, 448-454.	1.7	65
275	Acute myocardial infarction, primary percutaneous coronary intervention and stent thrombosis in heart transplanted patient: Potential role of elevated coagulation factor VIII. Cor Et Vasa, 2014, 56, e311-e315.	0.1	0
276	Lung Function Abnormalities are Highly Frequent in Patients with Heart Failure and Preserved Ejection Fraction. Heart Lung and Circulation, 2014, 23, 273-279.	0.4	35
277	The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) Tj ETQq1 1 0,784314 regBT /Over	2.9	80
278	Coronary Kinking in a Marathon Runner: A “Dangerous Liaison”? Revista Espanola De Cardiologia (English Ed ), 2014, 67, 767.	0.6	0
279	Effectiveness and Safety Beyond 10 Years of Percutaneous Transluminal Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 353-358.	0.6	12
280	Impact of therapeutic hypothermia on coronary flow. International Journal of Cardiology, 2014, 172, 228-229.	1.7	6
281	Tortuosidad arterial coronaria en un corredor de maratón: ¿una “relación peligrosa”? Revista Espanola De Cardiologia, 2014, 67, 767.	1.2	0
282	Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segment “Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 294-300.	3.9	30
283	Nitric-oxide Coated Bioactive Titanium Stents: Safer and More Effective Than Second-generation Drug-eluting Stents?. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 511-513.	0.6	0
284	Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy. Circulation Journal, 2014, 78, 1531-1539.	1.6	19
285	Edge Vascular Response After Polymer-Free vs. Polymer-Based Paclitaxel-Eluting Stent Implantation. Circulation Journal, 2014, 78, 2657-2664.	1.6	1
286	Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?. EuroIntervention, 2014, 10, 600-600.	3.2	14
287	Does manual thrombus aspiration help optimize stent implantation in ST-segment elevation myocardial infarction?. World Journal of Cardiology, 2014, 6, 1030.	1.5	5
288	Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?. World Journal of Cardiology, 2014, 6, 929.	1.5	2

#	ARTICLE	IF	CITATIONS
289	Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. World Journal of Cardiology, 2014, 6, 213.	1.5	0
290	Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry. International Journal of Cardiology, 2013, 168, 2522-2527.	1.7	1
291	First experience of a bioresorbable vascular scaffold implantation in left main stenosis. International Journal of Cardiology, 2013, 168, 1566-1568.	1.7	13
292	Update on Interventional Cardiology. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 282-289.	0.6	4
293	Techniques and material used in the percutaneous treatment of chronic coronary occlusions. Data from the CIBELES study. Revista Portuguesa De Cardiologia, 2013, 32, 593-599.	0.5	3
294	In-hospital and Mid-term Predictors of Mortality After Transcatheter Aortic Valve Implantation: Data From the TAVI National Registry 2010-2011. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 949-958.	0.6	22
295	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial. American Heart Journal, 2013, 166, 669-675.	2.7	19
296	Anticoagulation With Otamixaban and Ischemic Events in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	7.4	58
297	Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography. International Journal of Cardiovascular Imaging, 2013, 29, 5-11.	1.5	16
298	Techniques and material used in the percutaneous treatment of chronic coronary occlusions. Data from the CIBELES study. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 593-599.	0.2	2
299	Predictores de mortalidad hospitalaria y a medio plazo tras elÂreemplazo valvular aÃ³rtico transcateÂter: datos delÂregistro nacional TAVI 2010-2011. Cirugia Cardiovascular, 2013, 20, 174-183.	0.1	3
300	Comentarios a la guÃa de prÃctica clÃnica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevaciÃ³n del segmento ST. Revista Espanola De Cardiologia, 2013, 66, 5-11.	1.2	42
301	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction. American Heart Journal, 2013, 166, 119-126.e1.	2.7	5
302	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 168, 2632-2636.	1.7	11
303	Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 496-504.	2.8	210
304	Improvement of myocardial function and perfusion after successful percutaneous revascularization in patients with chronic total coronary occlusion. International Journal of Cardiology, 2013, 169, 147-152.	1.7	29
305	Hypothermia in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2013, 61, 686-687.	2.8	69
306	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915

#	ARTICLE	IF	CITATIONS
307	Percutaneous transcatheter aortic valve implantation: present and future perspective. Expert Review of Medical Devices, 2013, 10, 185-199.	2.8	7
308	Randomized Comparison of Sirolimus-Eluting and Everolimus-Eluting Coronary Stents in the Treatment of Total Coronary Occlusions. Circulation: Cardiovascular Interventions, 2013, 6, 21-28.	3.9	60
309	Organized Thrombus, Disorganized Heart. Circulation Journal, 2013, 77, 1152-1153.	1.6	0
310	One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent. Catheterization and Cardiovascular Interventions, 2013, 82, E428-36.	1.7	6
311	Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention, 2013, 8, 1242-1251.	3.2	336
312	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention, 2013, 8, 1362-1371.	3.2	168
313	Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. EuroIntervention, 2013, 9, 328-335.	3.2	20
314	The European Heart Journal and EuroIntervention: information and education in interventional cardiology. EuroIntervention, 2013, 9, 669-680.	3.2	1
315	First-in-man, last in evidence?. EuroIntervention, 2013, 8, 999-1001.	3.2	0
316	Transcatheter aortic valve implantation in patients with left main percutaneous coronary intervention. Journal of Heart Valve Disease, 2013, 22, 874-7.	0.5	2
317	Accurate Coronary Centerline Extraction, Caliber Estimation, and Catheter Detection in Angiographies. IEEE Transactions on Information Technology in Biomedicine, 2012, 16, 1332-1340.	3.2	49
318	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, The, 2012, 379, 1393-1402.	13.7	854
319	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	13.7	412
320	Comments on the ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 125-130.	0.6	0
321	Spanish Cardiac Catheterization and Coronary Intervention Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2011). Revista Espanola De Cardiologia (English Ed ), 2012, 65, 1106-1116.	0.6	3
322	Isolated right ventricular infarction presenting with anterior ST-segment elevation: A case for careful assessment of right ventricular branch occlusion. Revista Portuguesa De Cardiologia, 2012, 31, 301-304.	0.5	7
323	STEMI Interventions. Interventional Cardiology Clinics, 2012, 1, 559-565.	0.4	6
324	Registro Español de Hemodinámica y Cardiología Intervencionista. XXI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2011). Revista Espanola De Cardiologia, 2012, 65, 1106-1116.	1.2	50

#	ARTICLE	IF	CITATIONS
325	Determinantes del Éxito de la revascularización de las oclusiones coronarias crónicas: estudio mediante tomografía computarizada con multidetectores. Revista Española De Cardiología, 2012, 65, 334-340.	1.2	18
326	Comentarios a la guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Revista Española De Cardiología, 2012, 65, 125-130.	1.2	21
327	Endothelial Function in Coronary Chronic Total Occlusions. Journal of the American College of Cardiology, 2012, 60, 871-872.	2.8	2
328	Double Antiplatelet Therapy After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2012, 60, 1333-1339.	2.8	68
329	Endothelial and Smooth Muscle Cells Dysfunction Distal to Recanalized Chronic Total Coronary Occlusions and the Relationship With the Collateral Connection Grade. JACC: Cardiovascular Interventions, 2012, 5, 170-178.	2.9	39
330	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. EuroIntervention, 2012, 8, 35-42.	3.2	45
331	Primary percutaneous coronary intervention: models of intervention in Spain. EuroIntervention, 2012, 8, P90-P93.	3.2	14
332	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 30-39.	2.8	58
333	Assessment of Dynamic Coronary Plaque Changes and the Clinical Consequences in Type-II Diabetic Patients: a Serial Intracoronary Ultrasound Study. Revista Española De Cardiología (English Ed ), 2011, 64, 557-563.	0.6	2
334	Spanish Cardiac Catheterization and Coronary Intervention Registry. 20th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2010). Revista Española De Cardiología (English Ed ), 2011, 64, 1012-1022.	0.6	5
335	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. Clinical Research in Cardiology, 2011, 100, 561-570.	3.3	38
336	Letter by Brugaletta et al Regarding Article, "Vascular Reactivity and Flow Characteristics of Radial Artery and Long Saphenous Vein Coronary Bypass Grafts: A 5-Year Follow-Up", Circulation, 2011, 123, e412; author reply e414.	1.6	0
337	Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. EuroIntervention, 2011, 6, 831-837.	3.2	9
338	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention, 2011, 7, 977-984.	3.2	41
339	Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation. Circulation, 2010, 122, 1017-1025.	1.6	98
340	Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2010, 55, 1139-1146.	2.8	193
341	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
342	A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion) Trial. EuroIntervention, 2010, 6, 1017-1025.	1.6	98

#	ARTICLE	IF	CITATIONS
343	Special Management of Diabetic Patients with STEMI. , 2010, , 183-196.		0
344	Scientific societies and clinical trials. EuroIntervention, 2010, 6, 185-188.	3.2	0
345	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. Vascular Health and Risk Management, 2009, 5, 101.	2.3	11
346	Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective. Expert Opinion on Pharmacotherapy, 2009, 10, 1047-1058.	1.8	18
347	Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes. Diabetes, 2009, 58, 209-214.	0.6	46
348	Letter by Brugaletta et al Regarding Article, "Interference of Drug-Eluting Stents and Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses" Circulation: Cardiovascular Interventions, 2009, 2, e1; author reply e2.	3.9	0
349	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213
350	In-vivo measurements of heart ischemia using transoesophageal electrical impedance. IFMBE Proceedings, 2009, , 1163-1166.	0.3	1
351	Secondary revascularisation following intracoronary brachytherapy. EuroIntervention, 2009, 5 Suppl D, D121-6.	3.2	1
352	Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2008, 24, 125-132.	1.5	8
353	Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2008, 24, 357-364.	1.5	18
354	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	2.6	25
355	Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: Results of a pooled analysis of two randomized studies. Catheterization and Cardiovascular Interventions, 2008, 72, 459-467.	1.7	25
356	Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis. Journal of the American College of Cardiology, 2008, 52, 1621-1627.	2.8	46
357	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.3	270
358	Stent thrombosis in the era of drug-eluting stents. , 2008, , 211-219.		3
359	Abstract from the ESTROFA registry. EuroIntervention, 2008, 4 Suppl C, C54-5.	3.2	0
360	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 2007, 356, 1030-1039.	27.0	1,182



#	ARTICLE	IF	CITATIONS
361	Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. <i>European Heart Journal</i> , 2007, 28, 1946-1952.	2.2	73
362	Anatomical and physiologic assessments in patients with small coronary artery disease: Final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. <i>American Heart Journal</i> , 2007, 153, 296.e1-296.e7.	2.7	51
363	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet</i> , The, 2007, 370, 937-948.	13.7	1,329
364	Cardiogenic shock at admission in patients with multivessel disease and acute myocardial infarction treated with percutaneous coronary intervention: Related factors. <i>International Journal of Cardiology</i> , 2007, 123, 29-33.	1.7	26
365	Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1541-1547.	2.8	335
366	Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 181-188.	1.7	17
367	Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. <i>Platelets</i> , 2006, 17, 586-590.	2.3	26
368	Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1895-1900.	2.4	214
369	A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2152-2160.	2.8	158
370	Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2172-2179.	2.8	87
371	Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment. <i>Journal of the American College of Cardiology</i> , 2006, 48, 298-304.	2.8	284
372	Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1139-1145.	2.8	51
373	Pathological Effects of Pulmonary Vein beta-Radiation in a Swine Model. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 662-669.	1.7	13
374	Intravascular Ultrasound in Patients with Challenging In-Stent Restenosis: Importance of Precise Stent Visualization. <i>Journal of Interventional Cardiology</i> , 2006, 19, 153-159.	1.2	3
375	Influence of Aspirin Resistance on Platelet Function Profiles in Patients on Long-Term Aspirin and Clopidogrel After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 38-43.	1.6	117
376	Intravascular Ultrasound Characterization of the "Black Hole" Phenomenon After Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2006, 97, 203-206.	1.6	25
377	Influence of the CD14 C260T Promoter Polymorphism on C-Reactive Protein Levels in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2006, 98, 1182-1184.	1.6	11
378	Intravascular Brachytherapy Versus Drug-Eluting Stents for the Treatment of Patients With Drug-Eluting Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 98, 1340-1344.	1.6	61



#	ARTICLE	IF	CITATIONS
379	Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease. <i>Diabetes</i> , 2006, 55, 780-784.	0.6	146
380	Sirolimus-Eluting Stents vs Brachytherapy for Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1837.	7.4	1
381	Primary percutaneous coronary intervention of an anomalous right coronary artery originating from the left sinus of valsalva. <i>Acute Cardiac Care</i> , 2006, 8, 229-232.	0.2	4
382	Variability in Platelet Aggregation Following Sustained Aspirin and Clopidogrel Treatment in Patients With Coronary Heart Disease and Influence of the 807 C/T Polymorphism of the Glycoprotein Ia Gene. <i>American Journal of Cardiology</i> , 2005, 96, 1095-1099.	1.6	60
383	Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment. <i>Diabetes</i> , 2005, 54, 2430-2435.	0.6	492
384	Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients. <i>Circulation</i> , 2005, 112, 2175-2183.	1.6	345
385	Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 635-646.	1.5	1
386	LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. <i>European Heart Journal</i> , 2005, 26, 2307-2312.	2.2	31
387	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2005, 9, 46-47.	0.0	0
388	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. <i>Thrombosis Research</i> , 2005, 115, 101-108.	1.7	154
389	Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. <i>Thrombosis Research</i> , 2005, 116, 491-497.	1.7	137
390	Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. <i>American Heart Journal</i> , 2005, 149, e1-e8.	2.7	23
391	Drug-eluting stent thrombosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 954-959.	2.8	505
392	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. <i>European Heart Journal</i> , 2004, 25, 1903-1910.	2.2	268
393	Effectiveness of percutaneous coronary interventions in nonagenarians. <i>American Journal of Cardiology</i> , 2004, 94, 1058-1060.	1.6	35
394	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance?. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 39-42.	1.7	6
395	Coronary stenting versus balloon angioplasty in small vessels. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1964-1972.	2.8	93
396	Intracoronary Brachytherapy After Stenting De Novo Lesions in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2004, 44, 520-527.	2.8	25

#	ARTICLE	IF	CITATIONS
397	807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 427-433.	1.0	49
398	Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. <i>European Heart Journal</i> , 2004, 25, 1829-1835.	2.2	19
399	PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 89-93.	1.0	88
400	Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. <i>Journal of Invasive Cardiology</i> , 2004, 16, 169-74.	0.4	142
401	Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. <i>Journal of Invasive Cardiology</i> , 2004, 16, 325-9.	0.4	23
402	Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes!. <i>Cardiovascular Radiation Medicine</i> , 2003, 4, 171-175.	0.6	7
403	Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: Potential rebound prothrombotic effect?. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 481-484.	1.7	6
404	Importance of diastolic fractional flow reserve and dobutamine challenge in physiologic assessment of myocardial bridging. <i>Journal of the American College of Cardiology</i> , 2003, 42, 226-233.	2.8	146
405	Predictors and implications of residual plaque burden after coronary stenting: An intravascular ultrasound study. <i>American Heart Journal</i> , 2003, 145, 254-261.	2.7	12
406	Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. <i>Journal of the American College of Cardiology</i> , 2002, 39, 281-287.	2.8	89
407	Early dysfunction and long-term improvement in endothelium-dependent vasodilation in the infarct-related artery after thrombolysis. <i>Journal of the American College of Cardiology</i> , 2002, 40, 257-265.	2.8	35
408	Pressure wire kinking, entanglement, and entrapment during intravascular ultrasound studies: A potentially dangerous complication. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 50, 221-225.	1.7	17
409	The ESSEX (European Scimed Stent Experience) study. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 50, 419-425.	1.7	5
410	Guidewire-induced coronary pseudostenosis as a source of error during physiological guidance of stent deployment. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 51, 91-94.	1.7	6
411	Three-dimensional intravascular ultrasonic volumetric quantification of stent recoil and neointimal formation of two new generation tubular stents. <i>American Journal of Cardiology</i> , 2000, 85, 135-139.	1.6	46
412	Initial results and long-term clinical and angiographic outcome of coronary stenting in women. <i>American Journal of Cardiology</i> , 2000, 86, 1380-1383.	1.6	38
413	The role of intravascular ultrasound imaging in vascular brachytherapy. <i>International Journal of Cardiovascular Interventions</i> , 2000, 3, 3-12.	0.5	4
414	Predictive factors and long-term evolution of early endothelial dysfunction after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 453-461.	0.6	10

#	ARTICLE	IF	CITATIONS
415	Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. Journal of the American College of Cardiology, 2000, 36, 1536-1541.	2.8	25
416	Fate of stent-related side branches after coronary intervention in patients with in-stent restenosis. Journal of the American College of Cardiology, 2000, 36, 1549-1556.	2.8	53
417	Coronary bifurcation stenting using dedicated bifurcation stents. Catheterization and Cardiovascular Interventions, 2000, 49, 105-111.	1.7	3
418	Intracoronary Ultrasound Longitudinal Reconstruction of a Postangioplasty Coronary Artery Dissection. Circulation, 1999, 99, E17.	1.6	3
419	Remodeling of atherosclerotic coronary arteries varies in relation to location and composition of plaque. American Journal of Cardiology, 1999, 84, 135-140.	1.6	65
420	Comparison of brachytherapy strategies based on dose-volume histograms derived from quantitative intravascular ultrasound. Cardiovascular Radiation Medicine, 1999, 1, 115-124.	0.6	17
421	Quantitative measurements of in-stent restenosis: A comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheterization and Cardiovascular Interventions, 1999, 48, 133-142.	1.7	28
422	Stent implantation through a self-expanding stent. International Journal of Cardiovascular Interventions, 1998, 1, 45-48.	0.5	1
423	Percutaneous Coronary Intervention in Diabetic Patients. , 0, , .		0